71 results
424B3
CYTH
Cyclo Therapeutics Inc - Ordinary Shares
21 Nov 23
Prospectus supplement
9:15am
study evaluated the safety and pharmacokinetics of Trappsol® Cyclo™ along with markers of cholesterol metabolism and markers of NPC during a 12-week … enrollment in the U.S. Phase I study commenced in September 2017, and in May 2020 Cyclo announced Top Line data showing a favorable safety
S-4/A
CYTH
Cyclo Therapeutics Inc - Ordinary Shares
20 Nov 23
Registration of securities issued in business combination transactions (amended)
8:50am
Phase I clinical plans for a randomized, double blind, parallel group study at a single clinical site in the U.S. The Phase I study evaluated the safety … I study commenced in September 2017, and in May 2020 Cyclo announced Top Line data showing a favorable safety and tolerability profile for Trappsol®
S-4
CYTH
Cyclo Therapeutics Inc - Ordinary Shares
7 Nov 23
Registration of securities issued in business combination transactions
4:45pm
. The Phase I study evaluated the safety and pharmacokinetics of Trappsol® Cyclo™ along with markers of cholesterol metabolism and markers of NPC during a 12 … enrollment in the U.S. Phase I study commenced in September 2017, and in May 2020 Cyclo announced Top Line data showing a favorable safety
8-K
EX-10.1
yagnpaqw9vwdce5xe
20 Oct 23
Unregistered Sales of Equity Securities
2:19pm
425
EX-2.1
43bpro5uoo
21 Sep 23
Business combination disclosure
4:28pm
8-K
EX-2.1
hj1zg7azo3of
21 Sep 23
Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement
4:28pm
8-K
EX-10.1
s3b4p9t2glynn360bx
5 Jun 23
Entry into a Material Definitive Agreement
9:22am
8-K
EX-10.1
q644z a4vgoy5nx
4 May 23
Unregistered Sales of Equity Securities
3:42pm
8-K
EX-10.1
4xgqs9 v3vyczdpg2a7j
24 Apr 23
Unregistered Sales of Equity Securities
9:24am